Dixie Lewis

Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein

Veronika Bachanová, Sarah Cooley, Todd E. DeFor et al. · Blood · 2014 · 432 citations

Life Sciences, Hematology, Immunology +16

Phase I Study of a Bispecific Ligand-Directed Toxin Targeting CD22 and CD19 (DT2219) for Refractory B-cell Malignancies

Veronika Bachanová, Arthur E. Frankel, Qing Cao et al. · Clinical Cancer Research · 2015 · 68 citations · Full text

Medicine, Oncology, Pharmacology +17

GTB-3550 TriKE™ for the Treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML) Safely Drives Natural Killer (NK) Cell Proliferation At Initial Dose Cohorts

Erica D. Warlick, Daniel J. Weisdorf, Daniel A. Vallera et al. · Blood · 2020 · 40 citations

Medicine, Oncology, Pharmacotherapy +16

Initial Clinical Activity of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma

Veronika Bachanová, Dixie Lewis, Joseph Maakaron et al. · Blood · 2020 · 38 citations

Life Sciences, Immunology, Oncology +16

444 GTB-3550 tri-specific killer engager TriKE™ drives NK cells expansion and cytotoxicity in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients

Martin Felices, Erica D. Warlick, Mark Juckett et al. · Regular and Young Investigator Award Abstracts · 2021 · 20 citations · Full text

Medicine, Immunology, Oncology +17